+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Drugs Market - Global Forecast 2026-2032- Product Image
Cancer Drugs Market - Global Forecast 2026-2032- Product Image
New

Cancer Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 195 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4989947
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The cancer drugs market is undergoing rapid evolution, with industry strategies being redefined by new therapeutic modalities, technological advances, and the shifting global healthcare environment. Senior executives navigating this space require clear, actionable insight to inform investment, development, and commercialization decisions.

Market Snapshot: Cancer Drugs Market Size and Growth

The Cancer Drugs Market grew from USD 172.06 billion in 2025 to USD 188.72 billion in 2026. It is projected to maintain robust momentum with a compound annual growth rate (CAGR) of 10.13%, reaching USD 338.29 billion by 2032. This sustained expansion is backed by increased demand for innovative therapies, ongoing R&D, and a rising global cancer burden. Pharmaceutical leaders and investors continue to focus on both established and emerging regions as opportunities proliferate, supported by diverse regulatory and reimbursement environments.

Scope & Segmentation of the Cancer Drugs Market

This comprehensive report delivers strategic segmentation to enable targeted market assessment and opportunity identification across multiple axes:

  • Drug Classifications: Chemotherapy agents, hormone therapies, advanced immunotherapies such as checkpoint inhibitors and CAR-T cell therapies, as well as targeted therapies including monoclonal antibodies and tyrosine kinase inhibitors.
  • Routes of Administration: Modalities tailored to care settings and patient requirements, spanning intravenous infusions, oral drugs, and both subcutaneous and intramuscular formulations.
  • Therapy Types: Coverage of monotherapies and combination regimens, with emphasis on the integration of personalized medicine and precision oncology approaches.
  • Cancer Indications: Breadth of coverage addressing major types such as breast, lung, pancreatic, liver, prostate, and colorectal cancers, alongside areas representing higher unmet clinical needs or unique R&D requirements.
  • Distribution Channels: Adaptation of hospital pharmacies, retail outlets, and home healthcare services to support ongoing therapy management and enhance patient convenience.
  • End Users: Diverse end-user profiles, including hospitals, clinics, ambulatory centers, and home healthcare providers, each influencing patterns of adoption, access, and market penetration.
  • Regional Coverage: Inclusive assessment of Americas, Europe, Middle East, Africa, and Asia Pacific, considering the impact of healthcare infrastructure and reimbursement dynamics unique to each geography.
  • Technological Innovations: The integration of digital health solutions, genomic profiling, companion diagnostics, and real-world data analytics to support next-generation drug development and optimize commercialization efforts.

Key Takeaways for Cancer Drugs Market Stakeholders

  • Precision medicine and immunotherapy now set the pace for innovation, expanding the spectrum and personalization of available cancer treatments for diverse patient populations.
  • The collaborative model—linking biopharma, academia, payers, and patient organizations—drives efficiencies in drug development, clinical trial execution, and regulatory engagement.
  • Digital tools and artificial intelligence are increasingly central to optimizing evidence generation, enabling more precise patient selection, and forecasting market demand trends.
  • Evolving models for value-based reimbursement and outcomes-based contracting are influencing how companies justify, secure, and maintain patient access for oncology products.
  • Market entry and commercialization strategies must adapt to the specific regulatory policies and payer structures prevalent in both mature and emerging markets.

Tariff Impact: Navigating US Policy Changes in Cancer Therapeutics

Recent United States import tariffs introduced in 2025 have heightened supply chain complexity within the cancer therapeutics sector. These policy changes impact both active pharmaceutical ingredients and finished product availability, compelling manufacturers to reexamine global sourcing and invest in alternate or domestic manufacturing solutions. As organizations reassess relationships with contract development and manufacturing partners, cost management, supply continuity, and time-to-market become critical considerations. Downstream, changes in tariff policy influence formulary design and utilization management practices, requiring agility from both healthcare providers and payers to safeguard patient access. This evolving landscape highlights the urgent need for risk mitigation and adaptive supply chain strategies in oncology drug markets.

Methodology & Data Sources

This analysis synthesizes primary insights from in-depth interviews with oncologists, regulatory authorities, payers, and senior industry executives. Supplemented by a proprietary database capturing global approvals and sales trends, findings are validated through expert workshops and advanced benchmarking analytics to ensure actionable, reliable market intelligence.

Why This Report Matters

  • Empowers senior leaders to align portfolio strategy and prioritize new oncology market entries with confidence.
  • Provides a framework for assessing technology-driven competitive advantages while addressing the regulatory and policy differences across regional markets.
  • Delivers targeted segmentation and trend-driven intelligence to inform effective investment, risk mitigation, and commercialization planning.

Conclusion

Success in the evolving cancer drugs market is anchored in robust market intelligence, effective cross-functional alignment, and organizational agility. This report equips decision-makers with contextual insights essential for capitalizing on opportunities and navigating complexity within the oncology sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Cancer Drugs Market, by Drug Type
8.1. Chemotherapy
8.1.1. Alkylating Agents
8.1.2. Antimetabolites
8.1.3. Antitumor Antibiotics
8.2. Hormone Therapy
8.3. Immunotherapy
8.4. Targeted Therapy
8.4.1. Apoptosis-inducing Drugs
8.4.2. Monoclonal Antibodies
8.4.3. Tyrosine Kinase Inhibitors (TKIs)
9. Cancer Drugs Market, by Administration Route
9.1. Intramuscular
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Cancer Drugs Market, by Therapy Type
10.1. Combination Therapy
10.2. Monotherapy
11. Cancer Drugs Market, by Cancer Type
11.1. Breast Cancer
11.2. Colorectal Cancer
11.3. Liver Cancer
11.4. Lung Cancer
11.5. Pancreatic Cancer
11.6. Prostate Cancer
12. Cancer Drugs Market, by End User
12.1. Ambulatory Care Centers
12.2. Home Healthcare
12.3. Hospitals & Clinics
13. Cancer Drugs Market, by Distribution Channel
13.1. Hospital Pharmacy
13.2. Retail Pharmacy
14. Cancer Drugs Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Cancer Drugs Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Cancer Drugs Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Cancer Drugs Market
18. China Cancer Drugs Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. AbbVie Inc.
19.6. Amgen Inc.
19.7. Astellas Pharma Inc
19.8. AstraZeneca PLC
19.9. Bayer AG
19.10. BeiGene, Ltd.
19.11. Bristol-Myers Squibb Company
19.12. Daiichi Sankyo Company, Limited
19.13. Dr. Reddy’s Laboratories Ltd.
19.14. Eli Lilly and Company
19.15. F. Hoffmann-La Roche Ltd
19.16. Fresenius Kabi AG
19.17. Getwell Oncology Pvt Ltd
19.18. GlaxoSmithKline plc
19.19. Incyte Corporation
19.20. Kite Pharma, Inc by Gilead Company
19.21. Medivir AB
19.22. Merck & Co., Inc.
19.23. Nammi Therapeutics, Inc.
19.24. Novartis AG
19.25. Pfizer Inc.
19.26. Sanofi S.A.
19.27. Sun Pharmaceutical Industries Ltd.
19.28. Taiho Pharmaceutical Co., Ltd. by Otsuka Holdings Co., Ltd.
19.29. Takeda Pharmaceutical Company Limited
List of Figures
FIGURE 1. GLOBAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CANCER DRUGS MARKET SIZE, BY APOPTOSIS-INDUCING DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CANCER DRUGS MARKET SIZE, BY APOPTOSIS-INDUCING DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CANCER DRUGS MARKET SIZE, BY APOPTOSIS-INDUCING DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CANCER DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CANCER DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CANCER DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CANCER DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CANCER DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CANCER DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CANCER DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL CANCER DRUGS MARKET SIZE, BY LIVER CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL CANCER DRUGS MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL CANCER DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL CANCER DRUGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL CANCER DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL CANCER DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL CANCER DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL CANCER DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL CANCER DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL CANCER DRUGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL CANCER DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL CANCER DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL CANCER DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL CANCER DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. AMERICAS CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 93. AMERICAS CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 94. AMERICAS CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 95. AMERICAS CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 96. AMERICAS CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 97. AMERICAS CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 98. AMERICAS CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 99. AMERICAS CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 101. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 104. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 105. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 106. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 107. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 112. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 114. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 115. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 116. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 117. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 118. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 128. EUROPE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. EUROPE CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 130. EUROPE CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 131. EUROPE CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 132. EUROPE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 133. EUROPE CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 134. EUROPE CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 135. EUROPE CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 136. EUROPE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 139. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 140. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 141. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 142. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 143. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 144. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 145. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 146. AFRICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. AFRICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 148. AFRICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 149. AFRICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 150. AFRICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 151. AFRICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 152. AFRICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 153. AFRICA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. AFRICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 161. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 164. GLOBAL CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 165. ASEAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. ASEAN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 167. ASEAN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 168. ASEAN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 169. ASEAN CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 170. ASEAN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 171. ASEAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 172. ASEAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 173. ASEAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 174. GCC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. GCC CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 176. GCC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 177. GCC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 178. GCC CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 179. GCC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 180. GCC CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 181. GCC CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. GCC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 192. BRICS CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. BRICS CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 194. BRICS CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 195. BRICS CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 196. BRICS CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 197. BRICS CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 198. BRICS CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 199. BRICS CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 200. BRICS CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 201. G7 CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 202. G7 CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 203. G7 CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 204. G7 CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 205. G7 CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 206. G7 CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 207. G7 CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 208. G7 CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 209. G7 CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 210. NATO CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 211. NATO CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 212. NATO CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 213. NATO CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 214. NATO CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 215. NATO CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 216. NATO CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 217. NATO CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 218. NATO CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 219. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 220. UNITED STATES CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 221. UNITED STATES CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 222. UNITED STATES CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 223. UNITED STATES CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 224. UNITED STATES CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 225. UNITED STATES CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 226. UNITED STATES CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 227. UNITED STATES CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 228. UNITED STATES CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 229. CHINA CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 230. CHINA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 231. CHINA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 232. CHINA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 233. CHINA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 234. CHINA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 235. CHINA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 236. CHINA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 237. CHINA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Cancer Drugs market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi AG
  • Getwell Oncology Pvt Ltd
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Kite Pharma, Inc by Gilead Company
  • Medivir AB
  • Merck & Co., Inc.
  • Nammi Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Taiho Pharmaceutical Co., Ltd. by Otsuka Holdings Co., Ltd.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages195
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 188.72 Billion
Forecasted Market Value ( USD ) by 2032 $ 338.29 Billion
Compound Annual Growth Rate10.1%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

United States Cancer Drugs Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2032 - Product Image

United States Cancer Drugs Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2032

  • Report
  • 80 Pages
  • United States
From
North America Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Country and Growth Forecast, 2023 - 2030 - Product Image

North America Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Country and Growth Forecast, 2023 - 2030

  • Report
  • 151 Pages
  • North America
From
Unlocking Opportunity: Dominate the Bi/Multispecific Drug in the Oncology Market with Confidence - Product Image

Unlocking Opportunity: Dominate the Bi/Multispecific Drug in the Oncology Market with Confidence

  • Directory
  • Global
From
Gynecological Cancer Drugs Market - Global Forecast 2026-2032 - Product Image

Gynecological Cancer Drugs Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Gastric Cancer Drugs Market - Global Forecast 2026-2032 - Product Image

Gastric Cancer Drugs Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From

About the Oncology Drugs Market

The Oncology Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat cancer. These drugs are used to treat a variety of cancers, including breast, lung, and prostate cancer. Oncology drugs are typically administered intravenously or orally, and can be used in combination with other treatments such as radiation and chemotherapy. The Oncology Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, and Roche. These companies are constantly researching and developing new drugs to treat cancer, as well as improving existing treatments. Additionally, many smaller companies are also involved in the Oncology Drugs market, providing innovative treatments and therapies. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.